Home › Compare › BNGOW vs RYLD

BNGOW vs RYLD: Dividend Comparison 2026

BNGOW yields 55555.56% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNGOW wins by $1.3694488476474725e+24M in total portfolio value
10 years
BNGOW
BNGOW
● Live price
55555.56%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.3694488476474725e+24M
Annual income
$1,364,616,913,224,020,300,000,000,000,000.00
Full BNGOW calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — BNGOW vs RYLD

📍 BNGOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNGOWRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNGOW + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BNGOW pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNGOW
Annual income on $10K today (after 15% tax)
$4,722,222.22/yr
After 10yr DRIP, annual income (after tax)
$1,159,924,376,240,417,200,000,000,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, BNGOW beats the other by $1,159,924,376,240,417,200,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNGOW + RYLD for your $10,000?

BNGOW: 50%RYLD: 50%
100% RYLD50/50100% BNGOW
Portfolio after 10yr
$6.847244238237362e+23M
Annual income
$682,308,456,612,010,100,000,000,000,000.00/yr
Blended yield
99.65%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNGOW buys
0
RYLD buys
0
No recent congressional trades found for BNGOW or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNGOWRYLD
Forward yield55555.56% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.3694488476474725e+24M$44.5K ✓
Annual income after 10y$1,364,616,913,224,020,300,000,000,000,000.00 ✓$2,587.35
Total dividends collected$1.3691317625593198e+24M$18.8K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BNGOW vs RYLD ($10,000, DRIP)

YearBNGOW PortfolioBNGOW Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$5,566,256$5,555,555.56$11,914$1,213.65+$5.55M → BNGOW
2$2,896,015,891$2,890,059,997.69$14,099$1,351.30+$2896.00M → BNGOW
3$1,408,372,313,122$1,405,273,576,118.65$16,580$1,494.55+$1408372.30M → BNGOW
4$640,202,141,193,643$638,695,182,818,602.40$19,384$1,642.61+$640202141.17M → BNGOW
5$272,022,320,879,523,800$271,337,304,588,446,620.00$22,535$1,794.70+$272022320879.50M → BNGOW
6$108,040,039,048,992,300,000$107,748,975,165,651,200,000.00$26,063$1,950.00+$108040039048992.27M → BNGOW
7$40,110,958,331,298,180,000,000$39,995,355,489,515,755,000,000.00$29,995$2,107.69+$40110958331298176.00M → BNGOW
8$13,920,190,362,947,560,000,000,000$13,877,271,637,533,070,000,000,000.00$34,361$2,266.99+$13920190362947559424.00M → BNGOW
9$4,515,826,563,973,900,600,000,000,000$4,500,931,960,285,546,600,000,000,000.00$39,194$2,427.12+$4.5158265639739007e+21M → BNGOW
10$1,369,448,847,647,472,600,000,000,000,000$1,364,616,913,224,020,300,000,000,000,000.00$44,525$2,587.35+$1.3694488476474725e+24M → BNGOW

BNGOW vs RYLD: Complete Analysis 2026

BNGOW — Stock

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Full BNGOW Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this BNGOW vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNGOW vs SCHDBNGOW vs JEPIBNGOW vs OBNGOW vs KOBNGOW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.